Pre- and postnatal factors in chronic lung disease: Implications for management

Paediatric Respiratory Reviews

Volumn 5, Issue SUPPL. A, 2004, Pages

  Martin, Richard J ^a   Walsh, Michele C ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXAMETHASONE; GLUCOCORTICOID; LUNG SURFACTANT; NITRIC OXIDE; OXYGEN; RECOMBINANT ENZYME; RETINOL; STEROID; SUPEROXIDE DISMUTASE;

ADRENAL INSUFFICIENCY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; CARDIOMYOPATHY; CHRONIC LUNG DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; FETUS LUNG MATURATION; GROWTH DISORDER; HUMAN; HYPERTENSION; LUNG DYSPLASIA; NEWBORN; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PERINATAL PERIOD; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRENATAL CARE; PRENATAL PERIOD; PRIORITY JOURNAL; RESPIRATORY FAILURE; SIDE EFFECT; BAROTRAUMA; LUNG FUNCTION; NEWBORN DISEASE; PRENATAL DRUG EXPOSURE; REVIEW; RISK FACTOR;

EID: 1342291347     PISSN: 15260542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-0542(04)90044-9     Document Type: Review

References (46)

1. Stevenson DK, Wright LL, Lemons JA, Oh W, Korones SB, Papile LA, Bauer CR, Stoll BJ, Tyson JE, Shankaran S, Fanaroff AA, Donovan EF, Ehrenkranz RA, Verter J. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol 1998; 179: 1632-1639.
2. Martin RJ, Walsh-Sukys MC. Bronchopulmonary dysplasia - no simple solution. N Engl J Med 1999; 340: 1036-1038.
3. Northway Jr WH, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane: bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357-368.
4. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Nero G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126: 605-610.
5. Jobe AH. The new BPD: An arrest of lung development. Pediatr Res 1999; 46: 641-643.
6. Charaffedine L, Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics 1999; 1103: 759-765.
7. Shenan AT, Dunn MS, Ohlsson A, Lemons K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82: 527-532.
8. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. NICHD/NHLBI/ORD Workshop Summary. Am J Respir Crit Care Med 2001; 163: 1723-1729.
9. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50: 515-525.
10. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol 1993; 168: 508-513.
11. Van Marter LJ, Allred EN, Leviton A, Pagano M, Parad R, Moore M, and the Neonatology Committee for the Developmental Epidemiology Network. Antenatal glucocorticoid treatment does not reduce chronic lung disease among surviving preterm infants. J Pediatr 2001; 138: 198-204.
12. Banks BA, Cnaan A, Morgan MA, Parer JT, Merrill JD, Ballard PL, Ballard RA, and the North American Thyrotropin-Releasing Hormone Study Group. Multiple courses of antenatal corticosteroids and outcome of premature neonates. Am J Obstet Gynecol 1999; 181: 709-717.
13. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328: 861-868.
14. Clark RH, Gerstmann DR, Jobe AH, Moffitt ST, Slutsky AS, Yoder BA. Lung injury in neonates: Causes, strategies for prevention, and long-term consequences. J Pediatr 2001; 139: 478-486.
15. Wells LR, Papile LA, Gardner MO, Hartenberger CR, Merker L. Impact of antenatal corticosteroid therapy in very low birth-weight infants on chronic lung disease and other morbidities of prematurity. J Perinatol 1999; 19: 578-581.
16. Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants (review). The Cochrane Database of Systematic Reviews: The Cochrane Library 2000; 2.
17. Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrøm K, Jacobsen T, for the Danish-Swedish Multicenter Study Group. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994; 331: 1051-1055.
18. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, Vilstrup CT. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997; 42: 348-355.
19. Davis J, Rosenfeld W, Parad R. Improved pulmonary outcome at one year corrected age in premature neonates treated with recombinant human superoxide dismutase. Pediatr Res 2000; 47: 395A.
20. Shenai JP, Mellen BG, Chytil F. Vitamin A status and postnatal dexamethasone treatment in bronchopulmonary dysplasia. Pediatrics 2000; 106: 547-553.
21. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA, for the National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely low birth-weight infants. N Engl J Med 1999; 340: 1962-1968.
22. Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, Kim BI. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-α, interleukin-1β, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997; 177: 825-830.
23. Groneck P, Götze-Speer B, Opperman M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 1994; 93: 712-718.
24. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, Krause-Steinrauf H, Verter J, Korones SB, Lemons JA, Fanaroff AA, Stevenson DK, Oh W, Ehrenkranz RA, Shankaran S. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med 1998; 338: 1112-1118.
25. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, Yurman S, Dolfin T, Kogan A, Dollberg S, Arbel E, Goldberg M, Gur I, Naor N, Sirota L, Mogilner S, Zaritsky A, Barak M, Gottfried E. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177-F181.
26. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, Jolesz FA, Volpe JJ. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001; 107: 217-221.
27. Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon BL, Demissie S, Frantz III ID. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 1999; 340: 1005-1010.
28. Bancalari E. Neonatal chronic lung disease. In: Fanaroff AA, Martin RJ (Editors), Neonatal/Perinatal Medicine, 7th Edition. Philadelphia, PA: Harcourt, 2002.
29. Sherman TS, Chen Z, Yuhanna IS, Lau KS, Margraf LR, Shaul PW. Nitric oxide synthase isoform expression in the developing lung epithelium. Am J Physiol Lung Cell Mol Physiol 1999; 276: L383-L390.
30. Potter CF, Dreshaj IA, Haxhiu MA, Stork EK, Chatburn RL, Martin RJ. Effect of exogenous and endogenous nitric oxide (NO) on the airway and tissue components of lung resistance in the newborn piglet. Pediatr Res 1997; 41: 886-891.
31. Jakupaj M, Martin RJ, Dreshaj IA, Potter CF, Haxhiu M, Ernsberger P. Role of endogenous NO in modulating airway contraction mediated by muscarinic receptors during development. Am J Physiol Lung Cell Mol Physiol 1997; 273: L531-L536.
32. Khassawneh MY, Dreshaj IA, Liu S, Chang CH, Haxhiu MA, Martin RJ. Endogenous nitric oxide modulates responses of tissue and airway resistance to vagal stimulation in piglets. J Appl Physiol 2002. In press.
33. Iben SC, Dreshaj IA, Farver CF, Haxhiu MA, Martin RJ. Role of endogenous nitric oxide in hyperoxia-induced airway hyperreactivity in maturing rats. J Appl Physiol 2000; 89: 1205-1212.
34. Hershenson MB, Wylam ME, Punjabi N, Umans JG, Schumacker PT, Mitchell RW, Solway J. Exposure of immature rats to hyperoxia increases tracheal smooth muscle stress generation in vitro. J Appl Physiol 1994; 76: 743-749.
35. Colasurdo GN, Loader JE, Graves JP, Larsen GL. Maturation of nonadrenergic noncholinergic inhibitory system in normal and allergen-sensitized rabbits. Am J Physiol 1994; 267: L739-L744 (Lung Cell Mol Physiol 11).
36. Mhanna MJ, Ferkol T, Martin RJ, Dreshaj IA, van Heeckeren AM, Kelley TJ, Haxhiu MA. Nitric oxide deficiency contributes to impairment of airway relaxation in cystic fibrosis mice. Am J Respir Cell Mol Biol 2001; 24: 621-626.
37. Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S, Walsh-Sukys MC, McCaffrey MJ, Cornfield DN, Bhutani VK, Cutter GR, Baier M, Abman SH. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999; 354: 1061-1065.
38. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999; 103: 610-618.
39. Hamad AM, Johnson SR, Knox AJ. Antiproliferative effects of NO and ANP in cultured human airway smooth muscle. Am J Physiol 1999; 277: L910-L918 (Lung Cell Mol Physiol 21).
40. Ekekezie II, Thibeault DW, Zwick DL, Rezaiekhaligh MH, Mabry SM, Morgan RE, Norberg M, Truog WE. Independent and combined effects of prolonged inhaled nitric oxide and oxygen on lung inflammation in newborn piglets. Biol Neonate 2000; 77: 37-44.
41. Turanlahti M, Pesonen E, Lassus P, Andersson S. Nitric oxide and hyperoxia in oxidative lung injury. Acta Paediatr 2000; 89: 966-970.
42. Gries DM, Tam EK, Blaisdell JM, Iwamoto LM, Fujiwara N, Uyehara CFT, Nakamura KT. Differential effects of inhaled nitric oxide and hyperoxia on pulmonary dysfunction in newborn guinea pigs. Am J Physiol Regulatory Integrative Comp Physiol 2000; 279: R1525-R1530.
43. Steinhorn RH, Albert G, Swartz DD, Russell JA, Levine CR, Davis JM. Recombinant human superoxide dismutase enhances the effect of inhaled nitric oxide in persistent pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 834-839.
44. Yuhanna IS, MacRitchie AN, Lantin-Hermoso RL, Wells LB, Shaul PW. Nitric oxide (NO) upregulates NO synthase expression in fetal intrapulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1999; 21: 629-636.
45. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099-2107.
46. Martin RJ. Nitric oxide for preemies - Not so fast. N Engl J Med 2003; 349: 2157.